News

November 14, 2019
|
Category:

Bayer and Dewpoint Therapeutics $100M partnership in cardiovascular and gynaecological diseases gains significant media attention

The announcement of Dewpoint Therapeutics $100M partnership Bayer to research new treatments for cardiovascular and gynecological diseases has received significant media attention. A selection of key coverage and analysis can be found via the links below.

Read more on nature.com

Read more on biocentury.com

Read more on fiercebiotech.com

Read more on xconomy.com

Read more on endpts.com

Media Contact

media@dewpointx.com

Investor Contact

Michael Fenn, PH.D.
Head of External Innovation
Dewpoint Therapeutics
mfenn@dewpointx.com
Dewpoint Therapeutics
451 D Street, Suite 104
Boston, MA 02210
USA
© 2019-2024 - Dewpoint Therapeutics

Design: SALIENCE Communication / Publiepress
Scientific animation: Visual Science